Pipeline Coverage Is a Vanity Metric Without Quality Adjustment

Pipeline coverage is the metric everyone tracks and no one trusts. The formula is simple: total pipeline divided by quota. A 3× coverage ratio is the common benchmark—if you have $3M in pipeline against a $1M quota, you should be able to close enough to hit the number.

Except you won't. Because that $3M includes deals that haven't been touched in 60 days. Deals with close dates that have slipped four times. Deals where the "champion" left the company. Aggregating these with real opportunities produces a coverage number that means nothing.

The useful version of coverage adjusts for quality. It answers a different question: "Of the pipeline that's likely to be real, how much is there?"

The Zombie Deal Problem

Every pipeline has zombie deals—opportunities that are technically open but will never close. They accumulate because reps don't want to close-lose deals (it looks bad), managers don't enforce hygiene (the pipeline looks healthier with them), and the CRM doesn't automatically age them out.

Common zombie characteristics:

• No activity in 45+ days (buyer or rep side)
• Close date pushed 3+ times
• Stage unchanged for 2× average stage duration
• Primary contact no longer at the company
• Last communication was the rep following up with no response

Research suggests the average B2B pipeline contains 20-40% dead or dying deals that haven't been formally closed-lost [1]. That means your 3× coverage is often closer to 2× when you exclude the deals that aren't real.

This explains the common pattern where pipeline coverage looks healthy but quota attainment falls short. The coverage was an illusion—the real pipeline was thinner than reported.

Quality-Adjusted Coverage

Quality-adjusted coverage applies a probability weight to each deal based on health signals, not just stage. The calculation:

1. Start with raw pipeline value
2. Apply a health multiplier to each deal (0.0 to 1.0)
3. Sum the adjusted values
4. Divide by quota

A $100K deal with a 0.3 health score contributes $30K to adjusted coverage. A $50K deal with a 0.9 health score contributes $45K. The smaller healthy deal is worth more in the coverage calculation than the larger unhealthy one.

Health multipliers can be derived from a scoring model or from simple rules:

• Full credit (1.0): Active engagement, multi-threaded, on pace
• Partial credit (0.5): Engaged but single-threaded, or minor velocity concerns
• Minimal credit (0.2): Stalled engagement, close date slipped
• No credit (0.0): Zombie criteria met

Even a crude version of this produces coverage numbers that better predict actual attainment.

Coverage by Segment Matters More

Aggregate coverage hides segment-level problems. You might have 3× coverage overall, but:

• 5× in SMB (more than enough)
• 2× in mid-market (marginal)
• 1.5× in enterprise (insufficient)

If your quota distribution is 30% SMB, 40% mid-market, 30% enterprise, the aggregate looks fine but mid-market and enterprise are at risk. The SMB surplus doesn't make up for the deficit elsewhere—you can't close enterprise quota with SMB deals.

Segment-level coverage is especially important when segments have different cycle times. Enterprise deals take longer to close, so pipeline needed for Q4 enterprise quota should already exist in Q2. Aggregate coverage that looks healthy in Q3 might already be too late for enterprise.

The Close Date Problem

Pipeline coverage implicitly assumes deals will close when reps say they will. But close dates are fiction in most CRMs—they're placeholders that get pushed forward, not predictions grounded in buyer behavior.

A better approach: bucket pipeline by likelihood of closing this period rather than by stated close date.

• Committed: Verbal or written commitment, final procurement steps underway
• Best case: Strong engagement, realistic timeline, but not yet committed
• Pipeline: Active opportunity, closing possible but not certain this period
• Upside: Early stage or stalled, could accelerate but unlikely

Coverage against each bucket tells a different story. 2× committed coverage is excellent. 5× upside coverage is meaningless.

When Coverage Isn't the Problem

Sometimes pipeline coverage is genuinely healthy—quality-adjusted, segment-appropriate, bucket-balanced—and teams still miss quota. In these cases, coverage isn't the problem. Win rate or deal slippage is.

If you have 3× quality-adjusted coverage and close 20% instead of the historical 33%, you'll miss despite adequate pipeline. The diagnosis shifts from "generate more pipeline" to "why are we winning fewer deals?"

If deals that were in "committed" bucket slip to next quarter at a higher rate than expected, the coverage was technically right but the forecast was wrong. The diagnosis is "why are committed deals slipping?"

Simple coverage metrics don't distinguish these scenarios. They all look like "we need more pipeline." Adjusted coverage helps identify whether the problem is quantity, quality, or execution.

What to Do This Week

Run your current pipeline through a zombie filter. Flag any deal that meets at least one criterion:

• No buyer activity in 30+ days
• Close date pushed 2+ times
• Stage unchanged for longer than average

Calculate two coverage numbers: total coverage and coverage excluding flagged deals. The gap between them is your zombie overhang—the amount by which you're overestimating real pipeline.

If the gap is more than 20%, you have a hygiene problem. Either clean the pipe (close-lose the zombies) or at minimum, stop counting them in coverage discussions. Pretending they're real just delays the recognition that you need more pipeline generation.

References

1. Rework Resources, "Deal Aging Management: Identifying and Addressing Stalled Opportunities," 2026. resources.rework.com